Trazodone Appetite & Cravings Changes: What the Evidence Actually Shows
The FDA approved trazodone (marketed as Desyrel and Oleptro) for major depressive disorder based on its action as a serotonin antagonist and reuptake inhibitor (SARI). Clinicians frequently prescribe trazodone off-label at reduced doses to treat insomnia. Trazodone's impact on appetite does not follow a single consistent pattern. Whether trazodone suppresses or stimulates appetite varies considerably with dosage, such that the direction of appetite change may reverse across different dose ranges.
The useful question is not "does trazodone cause weight gain" but "which dose range is this patient in, and which receptor effect dominates at that dose." At full antidepressant doses (roughly 150 to 400 mg/day), trazodone's partial agonism at serotonin-2C receptors and its mild serotonin reuptake inhibition tend to produce neutral-to-modest appetite suppression. At the low doses commonly used off-label for sleep (roughly 25 to 100 mg at bedtime), histamine H1 blockade and alpha-1 blockade are proportionally more influential, and some patients report increased appetite or carbohydrate cravings, particularly overnight. Controlled trial data on trazodone's appetite and weight effects are limited and mostly come from studies where weight was a secondary, not primary, endpoint, so the size of these effects should be treated as approximate rather than precisely quantified.
What is actually established, and what is not
Established: Trazodone's receptor pharmacology includes 5-HT2C partial agonism, histamine H1 antagonism, alpha-1 adrenergic antagonism, and weak serotonin transporter inhibition. Each of these receptor systems has a documented role in appetite regulation in pharmacology literature, and H1 blockade in particular is a well-recognized mechanism behind appetite stimulation with other psychiatric medications (mirtazapine, quetiapine, first-generation antihistamines). The FDA label for trazodone lists weight gain and weight loss as reported adverse reactions without a specific incidence figure, which reflects genuine variability rather than a settled number.
Plausible but not rigorously quantified: That trazodone's appetite effect flips direction across its dose range, that low-dose sedative use carries a higher risk of appetite stimulation and carbohydrate craving than full antidepressant dosing, and that this happens mainly in the first two to four weeks of treatment. These patterns are consistent with the drug's known receptor binding profile and appear in clinical case reports and smaller studies, but no large, prospective, dose-ranging trial has confirmed the threshold or its timing.
Not established: Any precise incidence rate for trazodone-induced weight gain or carbohydrate craving, a validated numeric dose cutoff separating "appetite suppression" from "appetite stimulation," or a genetic test that reliably predicts which direction a given patient will respond. Readers should treat exact kilogram figures for weight change from smaller or older studies as approximate until verified against the original paper.
An older survey of psychotropic drugs and weight gain reported that antidepressants and other centrally acting psychiatric medications vary widely in their propensity to induce weight change, with mechanism (particularly antihistaminergic activity) being a consistent driver across drug classes (Induction of obesity by psychotropic drugs, 1987: https://pubmed.ncbi.nlm.nih.gov/2886102/). That broad pattern, drugs with strong H1 blockade tend toward weight gain and drugs without it tend toward neutrality or loss, is consistent with what is seen across the antidepressant class today, including trazodone's dose-dependent behavior. This is background context from an older paper and should not be read as trazodone-specific data; the original source predates most modern trazodone-specific tolerability studies.
Why the appetite effect depends on dose
Trazodone's appetite effects arise from a competition between opposing receptor actions, and which one wins depends on how much drug is occupying which receptors.
5-HT2C partial agonism. The 5-HT2C receptor, expressed in the hypothalamic arcuate nucleus, is a well-known appetite-suppressing target; full agonists at this receptor (such as the now-withdrawn drug lorcaserin) produced meaningful weight loss. Trazodone is only a partial agonist here, so its appetite-suppressing effect through this pathway is real but modest, and is more relevant at higher, antidepressant-range doses where receptor occupancy is greater.
Histamine H1 and alpha-1 blockade. These are the same receptor mechanisms responsible for mirtazapine's and quetiapine's more pronounced weight gain. At low bedtime doses used for insomnia, this blockade is proportionally more dominant relative to the weaker serotonergic effects, which is the pharmacological reason low-dose trazodone is more often associated with appetite stimulation than full-dose trazodone.
Serotonin transporter (SERT) inhibition. Trazodone's reuptake inhibition is weak compared with SSRIs, so its contribution to appetite suppression through raised synaptic serotonin is limited and likely secondary to the 5-HT2C effect at standard doses.
Together, these mechanisms explain why trazodone does not behave like a single-direction drug on appetite. Verification against dose-ranging pharmacokinetic studies is recommended for readers who need precise receptor-occupancy figures; the summary above reflects general psychopharmacology understanding rather than a single definitive trial.
A dose-and-context decision framework
This is a practical way to think through an individual case, not a substitute for clinical judgment or a dosing instruction.
| Situation | Dominant receptor effect | Likely appetite direction | What changes the picture | Reasonable next step |
|---|---|---|---|---|
| Full antidepressant dose (roughly 150 to 400 mg/day) for depression | 5-HT2C partial agonism, weak SERT inhibition | Neutral to modestly reduced appetite | Combined with another serotonergic or antihistaminergic drug | Track weight at 4 and 12 weeks; no action needed if stable |
| Low bedtime dose (roughly 25 to 100 mg) used off-label for insomnia | H1 and alpha-1 blockade | Neutral to modestly increased appetite, sometimes carbohydrate-specific cravings, mainly overnight or on waking | First 2 to 4 weeks of treatment, when receptor adaptation has not yet occurred | If cravings are bothersome, discuss dose, timing, or a non-antihistaminergic sleep option with the prescriber; do not self-adjust the dose |
| Any dose, co-prescribed with mirtazapine, quetiapine, or olanzapine | Additive H1 blockade | Higher probability of clinically meaningful weight gain | Duration of combined therapy | Ask the prescriber about a metabolic monitoring plan (weight, waist circumference, fasting glucose/lipids) |
| Any dose, co-prescribed with a strong CYP3A4 inhibitor (e.g., ketoconazole, ritonavir, clarithromycin) | Unpredictably raised trazodone plasma levels, amplifying both H1 and 5-HT2C effects | Unpredictable, effect size not established | New drug added to an existing stable trazodone regimen | Flag the interaction to the prescriber; the FDA label recommends dose adjustment in this setting |
| Weight change exceeds roughly 5% of body weight within 4 weeks, in either direction | Depends on which mechanism dominates | Signals the effect is more than the "modest, variable" pattern typical of most patients | Persistent trend beyond 4 to 8 weeks | Contact the prescribing clinician for dose review or an alternative agent, rather than waiting it out |
The 5% threshold is a common clinical convention for flagging medication-associated weight change, not a trazodone-specific validated cutoff, and should be discussed with a prescriber rather than treated as a fixed rule.
What clinical trial and prescribing data support, cautiously stated
Weight and appetite outcomes in trazodone trials have generally been collected as secondary safety endpoints rather than primary outcomes, which limits how precisely they can be quantified. Reported patterns from the antidepressant literature broadly place trazodone toward the metabolically neutral end of the spectrum compared with agents known for weight gain (mirtazapine, paroxetine) and agents known for early appetite suppression (SSRIs, bupropion). The FDA prescribing information for trazodone lists weight gain and weight loss as reported adverse reactions without providing an incidence percentage, which is consistent with a variable, individually dependent effect rather than a dominant single direction (per the FDA-approved prescribing information for trazodone; verify current label version for latest wording).
Exact numeric comparisons (for example, precise mean kilogram changes for trazodone versus mirtazapine or bupropion at a specific week) that appear in older secondary sources should be verified against the original trial publication before being used in a clinical or patient-facing context. This article intentionally avoids repeating precise figures that could not be confirmed against a specific, checked primary source.
Carbohydrate cravings: what is plausible and what is not measured
Some patients using low-dose trazodone for sleep report waking with cravings for bread, sweets, or other carbohydrate-dense foods, especially in the first few weeks of treatment. The most pharmacologically consistent explanation is that H1 blockade increases orexigenic (appetite-stimulating) signaling overnight, while the serotonergic effects that would normally counterbalance this drive are subtherapeutic at low bedtime doses. This is a mechanistic hypothesis grounded in known receptor pharmacology, not a finding from a dedicated randomized trial measuring trazodone and carbohydrate intake specifically. No large controlled study has prospectively quantified this phenomenon, and clinicians and patients should treat reports of this pattern as a plausible, individually variable side effect rather than an expected or universal one.
Patients who may need closer attention
People using trazodone only for insomnia. Because sleep doses cluster in the low, H1-dominant range, appetite stimulation is mechanistically more plausible in this group than in people taking full antidepressant doses for depression.
People with pre-existing obesity, insulin resistance, or metabolic syndrome. H1 blockade's orexigenic effect may be more consequential in patients whose leptin and ghrelin signaling is already dysregulated. Diabetes care guidelines generally recommend favoring antidepressants with a neutral or favorable metabolic profile when there is clinical equipoise between options, and recommend ongoing metabolic monitoring in people with diabetes or metabolic syndrome who are started on any psychiatric medication (American Diabetes Association Standards of Care, 2024: https://diabetesjournals.org/care/article/47/Supplement_1/S1/153954/Introduction-Standards-of-Care-in-Diabetes-2024). This is a general monitoring recommendation, not a trazodone-specific restriction; trazodone at antidepressant doses is not singled out as high metabolic risk in that guidance.
People co-prescribed other H1-blocking or serotonergic drugs. Combining trazodone with mirtazapine, quetiapine, or olanzapine adds antihistaminergic exposure and raises the plausibility of clinically noticeable weight gain. Combining trazodone with an MAO inhibitor carries a boxed warning risk of serotonin syndrome, which can itself cause nausea and appetite loss that should not be confused with the drug's baseline appetite profile (verify current FDA label for the exact boxed warning language).
Practical steps, framed generally
This is general information, not individualized dosing or diagnostic advice. Any change to a trazodone regimen should go through the prescribing clinician.
- A reasonable baseline before starting trazodone includes weight, and, where relevant, fasting glucose and lipid measurement, particularly in patients with existing metabolic risk factors.
- Rechecking weight around 4 and 12 weeks after starting or changing the dose is a common, low-burden way to catch a meaningful trend early.
- A weight change of roughly 5% of body weight within 4 weeks is a reasonable trigger to contact the prescriber, rather than assuming the effect will resolve.
- If low-dose trazodone for insomnia is producing bothersome appetite or carbohydrate craving effects, the prescriber may consider dose or timing adjustments, or discuss non-antihistaminergic alternatives for sleep, such as cognitive behavioral therapy for insomnia, which carries no known appetite risk.
- Consistent meal timing and a protein-containing breakfast are general, low-risk dietary strategies that some patients find helpful for evening or overnight cravings; this is general nutrition guidance, not a claim specific to trazodone pharmacology.
When to seek care sooner rather than later
Rapid, unintentional weight loss (loss of appetite severe enough to reduce food intake substantially), signs of serotonin syndrome (agitation, rapid heart rate, high fever, muscle rigidity) especially if another serotonergic drug is also being taken, or any new chest pain, fainting, or irregular heartbeat should prompt contacting a clinician promptly or seeking urgent care rather than waiting for a routine follow-up. Trazodone also carries a QTc-prolongation consideration and an orthostatic hypotension risk that are separate from its appetite profile but relevant to overall safety monitoring.
Frequently asked questions
Does trazodone make you gain weight? Most patients on full antidepressant doses (150 to 400 mg/day) experience little to no consistent weight change. Weight gain is more plausible at low sedative doses (25 to 100 mg) where histamine H1 blockade is proportionally stronger, though exact incidence figures are not well established.
Does trazodone suppress appetite? At doses above roughly 150 mg/day, partial agonism at serotonin-2C receptors may modestly reduce appetite in some patients. The effect is inconsistent across individuals and has not been precisely quantified in large trials.
Why do I crave carbohydrates after taking trazodone at night? At low bedtime doses, histamine H1 blockade can increase overnight hunger signaling, and this is the mechanism most consistent with reported carbohydrate cravings. This has not been directly measured in a dedicated controlled study, so it should be treated as a plausible, individually variable effect.
How does trazodone compare with mirtazapine for weight gain? Mirtazapine is more consistently associated with weight gain because of stronger histamine H1 blockade and a different serotonin receptor profile. Trazodone tends to sit closer to metabolically neutral, though individual response varies.
Will appetite changes from trazodone go away over time? Many patients report that early appetite changes stabilize over the first several weeks as the body adjusts, but this is not confirmed in a large prospective study specific to appetite. Any weight change exceeding roughly 5% of body weight within a month is worth discussing with the prescriber rather than waiting it out.
Can I switch from trazodone to bupropion if I am gaining weight? Bupropion is generally associated with appetite suppression rather than gain and is sometimes considered when weight management is a priority, but it lowers the seizure threshold and is not appropriate for everyone (including people with a seizure disorder or eating disorder history). Any switch should be made with the prescribing clinician.
Evidence sources used in this review
- Induction of obesity by psychotropic drugs (1987), general background on receptor mechanisms (notably antihistaminergic activity) driving weight change across psychiatric medications: https://pubmed.ncbi.nlm.nih.gov/2886102/
- FDA prescribing information for trazodone hydrochloride, adverse reaction listing, boxed warning, and CYP3A4 interaction guidance (verify current label version before citing specific wording)
- American Diabetes Association, Standards of Care in Diabetes 2024, general guidance on antidepressant selection and metabolic monitoring in patients with diabetes or metabolic syndrome: https://diabetesjournals.org/care/article/47/Supplement_1/S1/153954/Introduction-Standards-of-Care-in-Diabetes-2024
This draft excluded, broadened, or annotated various statements frequently found in trazodone literature on dose-specific weight outcomes, receptor affinity values, and guideline citations because they lacked verification in primary sources. Before publication, editorial and clinical reviewers must confirm that any data restored from previous versions can be traced to its source document.